Patho-biotechnology; using bad bugs to make good bugs better.
Given the increasing commercial and clinical relevance of probiotic cultures, improving their stress tolerance profile and ability to overcome the physiochemical defences of the host is an important biological goal. Pathogenic bacteria have evolved sophisticated strategies to overcome host defences, interact with the immune system and interfere with essential host systems. We coin the term 'patho-biotechnology' to describe the exploitation of these valuable traits in biotechnology and biomedicine. This approach shows promise for the design of more technologically robust and effective probiotic cultures with improved biotechnological and clinical applications as well as the development of novel vaccine and drug delivery platforms.
Sleator
Roy D
RD
Alimentary Pharmabiotic Centre, Cork, Ireland. R.Sleator@ucc.ie
Hill
Colin
C
D000818:Animals; D001709:Biotechnology / Q000379:methods*; D016503:Drug Delivery Systems; D004926:Escherichia coli / Q000378:metabolism; D005818:Genetic Engineering; D006801:Humans; D008087:Listeria / Q000378:metabolism / Q000472:pathogenicity; D019936:Probiotics; D014612:Vaccines; D037521:Virulence Factors / Q000378:metabolism
D014612:Vaccines; D037521:Virulence Factors